责任编辑：小浪快报 资料显示，上海益诺思生物技术股份有限公司位于中国(上海)自由贸易试验区郭守敬路199号106室，成 立日期2010年5月12日，上市日期2024年9月3日，公司主营业务涉及专业提供生物医药非临床研究服务 为主的综合研发服务(CRO)。主营业务收入构成为：非临床96.31%，临床3.42%，其他0.27%。 截至6月30日，益诺思股东户数5386.00，较上期减少0.90%；人均流通股5235股，较上期增加0.91%。 2025年1月-6月，益诺思实现营业收入3.75亿元，同比减少38.04%；归母净利润-1518.95万元，同比减少 115.88%。 分红方面，益诺思A股上市后累计派现4511.35万元。 机构持仓方面，截止2025年6月30日，益诺思十大流通股东中，工银医疗保健股票（000831）位居第七 大流通股东，持股43.94万股，相比上期增加7.23万股。工银战略转型股票A（000991）位居第九大流通 股东，持股35.41万股，为新进股东。嘉实医药健康股票A（005303）位居第十大流通股东，持股34.43 万股，为新进股东。农银医疗保健股票（000913）、中欧医疗健康混合A ...

分红方面，益诺思A股上市后累计派现4511.35万元。 9月25日，益诺思涨2.46%，成交额1.07亿元。两融数据显示，当日益诺思获融资买入额1081.18万元， 融资偿还852.66万元，融资净买入228.52万元。截至9月25日，益诺思融资融券余额合计7502.74万元。 机构持仓方面，截止2025年6月30日，益诺思十大流通股东中，工银医疗保健股票（000831）位居第七 大流通股东，持股43.94万股，相比上期增加7.23万股。工银战略转型股票A（000991）位居第九大流通 股东，持股35.41万股，为新进股东。嘉实医药健康股票A（005303）位居第十大流通股东，持股34.43 万股，为新进股东。农银医疗保健股票（000913）、中欧医疗健康混合A（003095）、中欧责任投资混 合A（009872）退出十大流通股东之列。 融资方面，益诺思当日融资买入1081.18万元。当前融资余额7502.74万元，占流通市值的1.67%，融资 余额低于近一年50%分位水平，处于较低位。 资料显示，上海益诺思生物技术股份有限公司位于中国(上海)自由贸易试验区郭守敬路199号106室，成 立日期2010年5月1 ...

Core Viewpoint - Yinos's stock price has shown significant growth this year, with a notable increase in recent trading days, indicating positive market sentiment towards the company [2]. Group 1: Stock Performance - Yinos's stock price increased by 25.04% year-to-date, with a 13.11% rise in the last five trading days, 5.09% in the last 20 days, and 36.90% over the last 60 days [2]. - As of September 17, Yinos's stock was trading at 44.00 CNY per share, with a market capitalization of 6.203 billion CNY [1]. Group 2: Financial Performance - For the first half of 2025, Yinos reported a revenue of 375 million CNY, a year-on-year decrease of 38.04%, and a net profit attributable to shareholders of -15.1895 million CNY, down 115.88% year-on-year [2]. - Cumulative cash dividends paid by Yinos since its A-share listing amount to 45.1135 million CNY [3]. Group 3: Shareholder Information - As of June 30, 2025, Yinos had 5,386 shareholders, a decrease of 0.90% from the previous period, with an average of 5,235 circulating shares per shareholder, an increase of 0.91% [2]. - Notable changes in institutional holdings include ICBC Medical Health Stock becoming the seventh largest shareholder, increasing its holdings by 72,300 shares, while new shareholders include ICBC Strategic Transformation Stock and Harvest Medical Health Stock [3].

Company Overview - Yinos Bio is located in the China (Shanghai) Pilot Free Trade Zone and was established on May 12, 2010. The company went public on September 3, 2024. Its main business involves providing non-clinical research services in the biopharmaceutical sector, primarily as a Contract Research Organization (CRO) [1] - The revenue composition of Yinos Bio is as follows: non-clinical services account for 96.31%, clinical services for 3.42%, and other services for 0.27% [1] Financial Performance - As of June 30, 2025, Yinos Bio reported a revenue of 375 million yuan, a year-on-year decrease of 38.04%. The net profit attributable to shareholders was -15.19 million yuan, representing a year-on-year decrease of 115.88% [2] - Since its A-share listing, Yinos Bio has distributed a total of 45.11 million yuan in dividends [3] Stock Performance - On September 12, Yinos Bio's stock price increased by 2.02%, reaching 39.98 yuan per share, with a trading volume of 46.57 million yuan and a turnover rate of 1.31%. The total market capitalization is 5.636 billion yuan [1] - Year-to-date, Yinos Bio's stock price has risen by 13.61%. However, it has seen a decline of 0.10% over the last five trading days and an 8.89% decrease over the last 20 days, while it has increased by 27.94% over the last 60 days [1] Shareholder Structure - As of June 30, 2025, the number of shareholders for Yinos Bio was 5,386, a decrease of 0.90% from the previous period. The average number of circulating shares per person increased by 0.91% to 5,235 shares [2] - Among the top ten circulating shareholders, ICBC Medical Health Stock (000831) is the seventh largest with 439,400 shares, an increase of 72,300 shares from the previous period. New entrants include ICBC Strategic Transformation Stock A (000991) and Harvest Medical Health Stock A (005303) [3]

Core Viewpoint - Yinosh experienced a slight increase in stock price on September 11, with a trading volume of 63.42 million yuan, indicating ongoing market activity despite financial challenges [1] Group 1: Financial Performance - For the first half of 2025, Yinosh reported a revenue of 375 million yuan, representing a year-on-year decrease of 38.04% [2] - The company recorded a net profit attributable to shareholders of -15.19 million yuan, a significant decline of 115.88% compared to the previous period [2] Group 2: Shareholder and Market Activity - As of June 30, 2025, Yinosh had 5,386 shareholders, a decrease of 0.90% from the previous period, while the average number of circulating shares per shareholder increased by 0.91% to 5,235 shares [2] - On September 11, Yinosh's financing buy-in amounted to 4.74 million yuan, with a net financing buy of -1.48 million yuan, indicating more repayments than new purchases [1] - The total balance of margin trading for Yinosh reached 87.06 million yuan, accounting for 2.45% of its market capitalization [1] Group 3: Shareholder Composition - As of June 30, 2025, the top ten circulating shareholders included ICBC Medical Health Stock, which increased its holdings by 72,300 shares to 439,400 shares [3] - New entrants among the top ten shareholders included ICBC Strategic Transformation Stock and Harvest Medical Health Stock, holding 354,100 shares and 344,300 shares respectively [3] - Notably, several funds such as Agricultural Bank Medical Health Stock and others exited the top ten circulating shareholders list [3]

Group 1 - On September 10, Yinos achieved a stock price increase of 3.57% with a trading volume of 79.4568 million yuan, and the net financing purchase amounted to 3.0738 million yuan [1] - As of September 10, the total balance of margin trading for Yinos was 88.5422 million yuan, which represents 2.51% of its circulating market value [1] - Yinos primarily operates in the field of biopharmaceutical non-clinical research services, with 96.31% of its revenue coming from non-clinical services [1] Group 2 - As of June 30, Yinos had 5,386 shareholders, a decrease of 0.90% from the previous period, while the average circulating shares per person increased by 0.91% to 5,235 shares [2] - For the first half of 2025, Yinos reported a revenue of 375 million yuan, a year-on-year decrease of 38.04%, and a net profit attributable to shareholders of -15.1895 million yuan, a decline of 115.88% [2] - After its A-share listing, Yinos has distributed a total of 45.1135 million yuan in dividends [2]

Group 1 - The core viewpoint of the news is that Yinosh has experienced a decline in stock price and financial performance, with significant changes in financing and shareholder structure [1][2][3] - As of September 2, Yinosh's stock price fell by 2.24%, with a trading volume of 58.6354 million yuan. The net financing buy was -3.902 million yuan, indicating a higher repayment than new purchases [1] - Yinosh's financing balance reached 86.1492 million yuan, accounting for 7.59% of its market capitalization, with no short selling activity reported on the same day [1] Group 2 - For the first half of 2025, Yinosh reported a revenue of 375 million yuan, a year-on-year decrease of 38.04%, and a net profit attributable to shareholders of -15.1895 million yuan, a decline of 115.88% [2] - As of June 30, 2025, the number of Yinosh shareholders was 5,386, a decrease of 0.90%, while the average circulating shares per person increased by 0.91% to 5,235 shares [2] - Yinosh has distributed a total of 45.1135 million yuan in dividends since its A-share listing, with changes in institutional holdings noted among its top shareholders [3]

Group 1 - The core revenue of the company for the first half of 2025 reached 375 million yuan, with new orders amounting to 532 million yuan, reflecting a year-on-year increase of 7.39% [1] - The total backlog of orders stood at 1.112 billion yuan, which is a 14.29% increase compared to the end of 2024 [1] - The company experienced growth across all business segments, with a combined year-on-year increase of 6.86% in new projects for IND and NDA applications [1] Group 2 - The company is a leading comprehensive R&D service provider in the biopharmaceutical non-clinical research sector, recognized for its international service capabilities [2] - As of June 30, 2025, the company has successfully assisted in over 200 innovative drug research services, including several groundbreaking therapies and products [2] - The strategic project in Nantong has been successfully implemented, covering an area of 24,000 square meters and featuring 130 international standard animal housing units, which will enhance the company's capacity and efficiency in innovative molecules and advanced therapies [2]

Core Insights - The company reported a revenue of 375 million yuan for the first half of 2025, impacted by a slowdown in investment and market demand in the domestic pharmaceutical industry, leading to increased competition and reduced sales order prices [1] - New order value reached 532 million yuan, a year-on-year increase of 7.39%, while the backlog of orders grew to 1.112 billion yuan, up 14.29% from the end of 2024 [1] - The company maintained a strong focus on R&D, with R&D expenditure as a percentage of revenue rising from 3.67% to 5.94%, reflecting a commitment to technological innovation and long-term growth potential [1] Business Performance - All business segments performed well, with the core IND and NDA new project numbers increasing by 6.86% year-on-year, showcasing the company's strong market expansion capabilities [1] - The company secured one new authorized invention patent during the reporting period, bringing the total number of authorized patents to 69 by the end of the reporting period [1] International Expansion - The company has established itself as a leading CRO in China, being one of the first to obtain GLP certifications from NMPA, OECD, and FDA, aligning with international standards [2] - Significant growth in international business new orders was noted, enhancing the company's recognition and influence in the global market [2] - The company has assisted in over 200 innovative drug research services, including several groundbreaking therapies and products, demonstrating its capability in both domestic and international markets [2] Capacity Development - The company successfully launched its strategic project in Nantong, covering an area of 24,000 square meters and planning 130 international standard animal housing units, which will enhance its capabilities in innovative molecules and advanced therapies [3]

Core Insights - Yinosh experienced a slight decline of 0.31% on August 22, with a trading volume of 55.43 million yuan [1] - The company reported a financing buy-in amount of 10.08 million yuan and a net financing buy of 0.61 million yuan on the same day [1] - As of August 22, the total financing and securities lending balance for Yinosh was 92.67 million yuan, accounting for 7.84% of its market capitalization [1] Financing and Securities Lending - On August 22, Yinosh had a financing buy-in of 10.08 million yuan, with a financing balance of 92.67 million yuan [1] - The company had no securities lending transactions on that day, with a remaining balance of 0.00 shares [1] Company Overview - Shanghai Yinosh Biotechnology Co., Ltd. was established on May 12, 2010, and is located in the China (Shanghai) Pilot Free Trade Zone [1] - The company specializes in providing comprehensive research and development services (CRO) primarily focused on non-clinical research in biomedicine, with 95.42% of its revenue coming from non-clinical services [1] - As of March 31, the number of shareholders was 5,435, a decrease of 46.05%, while the average circulating shares per person increased by 97.22% to 5,187 shares [1] Financial Performance - For the period from January to March 2025, Yinosh reported a revenue of 209 million yuan and a net profit attributable to shareholders of 5.52 million yuan, reflecting a year-on-year decrease of 90.30% [1] - Since its A-share listing, Yinosh has distributed a total of 45.11 million yuan in dividends [2] Institutional Holdings - As of March 31, 2025, the top ten circulating shareholders included notable institutional investors such as Agricultural Bank of China Medical Health Stock and China Europe Medical Health Mixed Fund, with varying increases in their holdings [2]